



# Correction: A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia

C. U. Correll<sup>1,2,3</sup> · Ofer Agid<sup>4</sup> · Benedicto Crespo-Facorro<sup>5</sup> · Andrea de Bartolomeis<sup>6</sup> · Andrea Fagiolini<sup>7</sup> · Niko Seppälä<sup>8</sup> · Oliver D. Howes<sup>9</sup>

Published online: 17 August 2022  
© The Author(s) 2022

**Correction: CNS Drugs (2022) 36:659–679**  
<https://doi.org/10.1007/s40263-022-00932-2>

This article was published online on June 27, 2022. An error was subsequently identified in the article, and the following correction should be noted:

In the original publication, section 4.6, page 667, the reference cited in the first full sentence in column 2 and in Table 5 on the same page that read:

“This information can be used to optimize clozapine dosage (Table 5) [103].”

“Table 5 Therapeutic drug monitoring (TDM)-informed decision-making algorithm for clozapine-treated patientsa [103]”

“Adapted by permission from reference [103]”

Should read:

“This information can be used to optimize clozapine dosage (Table 5) [104].”

“Table 5 Therapeutic drug monitoring (TDM)-informed decision-making algorithm for clozapine-treated patientsa [104]”

“Adapted by permission from reference [104]”

The original article has been corrected.

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s40263-022-00932-2>.

✉ Oliver D. Howes  
oliver.howes@kcl.ac.uk

<sup>1</sup> Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany

<sup>2</sup> Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA

<sup>3</sup> Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA

<sup>4</sup> Department of Psychiatry, University of Toronto, Toronto, Canada

<sup>5</sup> CIBERSAM, Hospital Universitario Virgen del Rocío, IBI-S, Universidad de Sevilla, Sevilla, Spain

<sup>6</sup> Section on Clinical Psychiatry and Psychology, Laboratory of Molecular and Translational Psychiatry and Unit of Treatment Resistant Psychosis, University of Naples Federico II, Naples, Italy

<sup>7</sup> Department of Molecular Medicine, University of Siena, Siena, Italy

<sup>8</sup> Department of Psychiatry Satasairaala, Harjavalta, Finland

<sup>9</sup> Institute of Psychiatry, Psychology and Neuroscience, King’s College, London, UK